Saltar al contenido
MilliporeSigma

Base editing rescue of spinal muscular atrophy in cells and in mice.

Science (New York, N.Y.) (2023-03-31)
Mandana Arbab, Zaneta Matuszek, Kaitlyn M Kray, Ailing Du, Gregory A Newby, Anton J Blatnik, Aditya Raguram, Michelle F Richter, Kevin T Zhao, Jonathan M Levy, Max W Shen, W David Arnold, Dan Wang, Jun Xie, Guangping Gao, Arthur H M Burghes, David R Liu
RESUMEN

Spinal muscular atrophy (SMA), the leading genetic cause of infant mortality, arises from survival motor neuron (SMN) protein insufficiency resulting from SMN1 loss. Approved therapies circumvent endogenous SMN regulation and require repeated dosing or may wane. We describe genome editing of SMN2, an insufficient copy of SMN1 harboring a C6>T mutation, to permanently restore SMN protein levels and rescue SMA phenotypes. We used nucleases or base editors to modify five SMN2 regulatory regions. Base editing converted SMN2 T6>C, restoring SMN protein levels to wild type. Adeno-associated virus serotype 9-mediated base editor delivery in Δ7SMA mice yielded 87% average T6>C conversion, improved motor function, and extended average life span, which was enhanced by one-time base editor and nusinersen coadministration (111 versus 17 days untreated). These findings demonstrate the potential of a one-time base editing treatment for SMA.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anticuerpo anti-NeuN, clon A60, clone A60, Chemicon®, from mouse
Sigma-Aldrich
Anticuerpo anti-colina acetiltransferasa, Chemicon®, from goat
Sigma-Aldrich
Smoothened Agonist, SAG, A cell-permeable Smoothened Agonist, SAG, CAS 364590-63-6, modulates the coupling of Smo with its downstream effector by interacting with the Smo heptahelical domain (KD = 59 nM).
Sigma-Aldrich
Anticuerpo anti-proteína gliofibrilar ácida, clon GA5, clone GA5, Chemicon®, from mouse